Ludwig, H., Sonneveld, P., Davies, F., Blade, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hajek, R., Sondergeld, P., Palumbo, A. (2014) European Perspective on Multiple Myeloma Treatment Strategies in 2014. ONCOLOGIST, 19 (8). pp. 829-844. ISSN 1083-7159

Full text not available from this repository.

Abstract

The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on "fitness," with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two-and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results. The Oncologist 2014; 19: 829-844

Item Type:	Article
Authors (ICR Faculty only):	Davies, Faith and Morgan, Gareth
All Authors:	Ludwig, H., Sonneveld, P., Davies, F., Blade, J., Boccadoro, M., Cavo, M., Morgan, G., de la Rubia, J., Delforge, M., Dimopoulos, M., Einsele, H., Facon, T., Goldschmidt, H., Moreau, P., Nahi, H., Plesner, T., San-Miguel, J., Hajek, R., Sondergeld, P., Palumbo, A.
Additional Information:	ISI Document Delivery No.: AO5UV Times Cited: 0 Cited Reference Count: 141 Ludwig, Heinz Sonneveld, Pieter Davies, Faith Blade, Joan Boccadoro, Mario Cavo, Michele Morgan, Gareth de la Rubia, Javier Delforge, Michel Dimopoulos, Meletios Einsele, Hermann Facon, Thierry Goldschmidt, Hartmut Moreau, Philippe Nahi, Hareth Plesner, Torben San-Miguel, Jesus Hajek, Roman Sondergeld, Pia Palumbo, Antonio Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA; Austrian Forum Against Cancer The consensus meeting has been supported by an unrestricted grant by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA. This work was supported in part by the Austrian Forum Against Cancer. This is a position paper from the European Myeloma Network. 0 ALPHAMED PRESS DURHAM ONCOLOGIST
Uncontrolled Keywords:	Multiple myeloma Risk stratification Consolidation Maintenance Autologous stem cell transplantation Nontransplant setting Elderly patients STEM-CELL TRANSPLANTATION MINIMAL RESIDUAL DISEASE TERM-FOLLOW-UP NEWLY-DIAGNOSED MYELOMA LOW-DOSE DEXAMETHASONE MULTIPARAMETER FLOW-CYTOMETRY INTERNATIONAL STAGING SYSTEM GROUP CONSENSUS STATEMENT HIGH-RISK CYTOGENETICS AUTOLOGOUS TRANSPLANTATION
Research teams:	ICR divisions > Clinical Studies > Molecular Haematology (including Cytogenetics Group and Cell Markers) ICR divisions > Molecular Pathology > Molecular Haematology (including Cytogenetics Group and Cell Markers) Closed research groups > Myeloma Targeted Treatment
Depositing User:	Barry Jenkins
Date Deposited:	08 Oct 2014 07:16
Last Modified:	16 Nov 2015 11:31
URI:	http://publications.icr.ac.uk/id/eprint/13589

Actions (login required)

View Item